SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2176719

Cover Image

PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2176719

Pet Longevity and Healthspan Market Forecasts to 2034 - Global Analysis By Intervention Type, Pet Type, Life Stage, Delivery Channel, Assessment and Diagnostics, Intervention Setting, and By Geography

PUBLISHED:
PAGES: 300+ Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4150
PDF (2-5 User License)
USD 5250
PDF & Excel (Site License)
USD 6350
PDF & Excel (Global Site License)
USD 7500

Add to Cart

According to Stratistics MRC, the Global Pet Longevity and Healthspan Market is accounted for $0.7 billion in 2026 and is expected to reach $1.3 billion by 2034 growing at a CAGR of 8.0% during the forecast period. The market covers preventive and advanced interventions intended to extend healthy years in companion animals, including biomarker testing, personalized nutrition, and wearables. It is used to identify risks earlier and maintain mobility, function and quality of life. Growth reflects owner investment in preventive care and scientific interest in companion-animal aging. Adoption will also depend on product reliability, affordability, professional guidance and availability through established distribution channels.

Market Dynamics:

Driver:

Preventive pet care and scientific interest in healthy aging

Owner investment in preventive care and scientific interest in companion-animal aging are driving the longevity and healthspan market. Biomarker testing, genetic risk profiling, personalized nutrition, wearables and regenerative therapies aim to extend healthy years and preserve function. Preventive blood panels and activity monitoring support early intervention. Humanization and willingness to pay for advanced care sustain premium services. Veterinary longevity clinics and research programs are expanding access, while digital platforms improve engagement and follow-up.

Restraint:

Long evidence timelines and uncertainty around longevity outcomes

Adoption is constrained by long evidence timelines and uncertainty around longevity outcomes. Interventions require years to demonstrate benefit, complicating validation and owner expectations. Many products lack robust clinical evidence. Costs for diagnostics, monitoring and therapies can be high. Regulatory pathways for regenerative and preventive interventions are unclear. Veterinary adoption varies, and access is concentrated in urban or specialty practices. Clear evidence, realistic claims and transparent pricing are essential.

Opportunity:

Biomarker-led monitoring and evidence-based preventive programs

Opportunity lies in biomarker-led monitoring, genetic risk profiling and evidence-based preventive programs. Longitudinal data and wearables support personalized recommendations. Veterinary longevity clinics and subscription monitoring create recurring revenue. Partnerships with diagnostics laboratories, insurers and research institutions expand credibility. Nutrition, supplementation and mobility programs can be bundled. Owner education on healthy aging and preventive screening supports engagement. Regional expansion and localized programs address diverse market needs.

Threat:

Regulatory ambiguity and hype around unproven interventions

The market faces risks from regulatory ambiguity, hype around unproven interventions and consumer skepticism. Weak evidence can damage trust and invite scrutiny. High costs and limited reimbursement constrain adoption. Competition from general preventive care and supplements fragments demand. Data privacy and genetic information concerns require safeguards. Companies need rigorous research, transparent communication and compliant marketing to sustain credibility and long-term growth.

Covid-19 Impact:

The COVID-19 pandemic disrupted veterinary appointments, specialist retail, travel and pet-care supply chains, while shifting more purchasing and advice-seeking online. Some owners postponed non-urgent services, but increased time at home and heightened attention to animal wellbeing supported demand for home-use products and digital support. Providers responded with e-commerce, teleconsultation and flexible scheduling. As restrictions eased, in-person services recovered, but demand for convenience and clear product information remained. The effect varied by market, depending on clinical need, discretionary spending and reliance on in-person experiences where available.

The Preventive Nutrition and Supplements segment is expected to be the largest during the forecast period

The Preventive Nutrition and Supplements segment is expected to account for a leading share of the pet longevity and healthspan market during the forecast period. Its position reflects the relevance of this group to the addressable companion-animal population and the breadth of use across the market's principal intervention type applications. Established product availability, owner familiarity and professional recommendations support demand, while a wide range of care needs encourages repeat purchasing or service use. Market participants are expected to prioritize this segment through targeted product development, broader distribution and clearer use guidance.

The Other Companion Animals segment is expected to have the highest CAGR during the forecast period

The Other Companion Animals segment is expected to have the highest CAGR during the forecast period as providers expand targeted solutions and improve access through veterinary, specialist retail and digital channels. Demand is supported by growing awareness of the relevant need, improved product formulation or service delivery, and increased owner willingness to invest in tailored companion-animal care. As evidence, convenience and availability improve, this segment may attract new entrants and encourage established providers to broaden their portfolios.

Region with largest share:

North America is expected to account for a leading share of the pet longevity and healthspan market, supported by high companion-animal ownership, comparatively developed veterinary infrastructure, established pet specialty retail and relatively high per-pet expenditure. The United States represents a major demand center because owners have access to veterinary clinics, online pet-care platforms and a broad selection of specialized products and services. Canada contributes through a mature pet-care ecosystem and established companion-animal health providers. Market adoption is also supported by insurance availability, consumer awareness and product innovation, although adoption differs by income, geography and veterinary access.

Region with highest CAGR:

Asia Pacific is expected to exhibit strong growth in the pet longevity and healthspan market as pet ownership, urban household formation, veterinary service availability and organized pet retail expand across major markets. China, Japan, South Korea, India and Australia offer different adoption pathways, reflecting differences in purchasing power, veterinary infrastructure, product regulation and the role of digital commerce. Growing awareness of preventive care and rising demand for premium companion-animal products are likely to support market development. Expansion will depend on localized products, professional education and compliance with national animal-health and consumer-protection requirements.

Key players in the market

Some of the key players in the Global Pet Longevity and Healthspan Market include Loyal, Rejuvenate Bio, Animal Bioscience, Gallant, VetStem, Inc., Embark Veterinary, Inc., Mars Petcare, Nestle Purina PetCare, Zoetis Inc., Hill's Pet Nutrition, PetDx, FidoCure, Basepaws, Wisdom Panel, Bioiberica.

Key Developments:

In September 2026, Fera Pets introduced a soft-chew formula positioned to support healthy aging, cellular energy and cognitive function in dogs.

In September 2026, Eugene Pet Wellness launched an AI-enabled platform designed to connect canine genetic information, individual health data and ongoing wellness decisions in a continuous owner-facing record.

In April 2026, Gallant announced positive pilot data for an intravenous cell therapy in cats with naturally occurring osteoarthritis and reported FDA eligibility for an expanded conditional-approval pathway.

Intervention Types Covered:

  • Preventive Nutrition and Supplements
  • Advanced Diagnostics and Biomarkers
  • Regenerative and Cellular Therapies
  • Personalized Veterinary Monitoring
  • Exercise and Mobility Programs

Pet Types Covered:

  • Dogs
  • Cats
  • Other Companion Animals

Life Stages Covered:

  • Adult Preventive Care
  • Mature-Age Healthspan
  • Senior Longevity Support

Delivery Channels Covered:

  • Veterinary Clinics
  • Specialty Wellness Providers
  • Online and Direct-to-Consumer
  • Diagnostic Laboratories

Assessments and Diagnostics Covered:

  • Preventive Blood and Biomarker Panels
  • Genetic and Risk Profiling
  • Wearable and Activity Monitoring
  • Functional and Mobility Assessment

Intervention Settings Covered:

  • Primary Veterinary Care
  • Specialty Longevity Clinics
  • Home-Based Preventive Programs
  • Research and Clinical Trial Programs

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for regional and country-level segments
  • Strategic recommendations for new entrants
  • Covers market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032, and 2034
  • Market trends, including drivers, constraints, opportunities, threats, challenges, investment opportunities, and recommendations
  • Strategic recommendations for key business segments based on market estimations
  • Competitive landscape mapping and assessment of key industry trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends and assessment of the latest technological advancements

Free Customization Offerings:

All customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, forecasts, and CAGR of any prominent country as per the client's interest (subject to feasibility assessment)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Product Code: SMRC41187

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Pet Longevity and Healthspan Market, By Intervention Type

  • 5.1 Preventive Nutrition and Supplements
  • 5.2 Advanced Diagnostics and Biomarkers
  • 5.3 Regenerative and Cellular Therapies
  • 5.4 Personalized Veterinary Monitoring
  • 5.5 Exercise and Mobility Programs

6 Global Pet Longevity and Healthspan Market, By Pet Type

  • 6.1 Dogs
  • 6.2 Cats
  • 6.3 Other Companion Animals

7 Global Pet Longevity and Healthspan Market, By Life Stage

  • 7.1 Adult Preventive Care
  • 7.2 Mature-Age Healthspan
  • 7.3 Senior Longevity Support

8 Global Pet Longevity and Healthspan Market, By Delivery Channel

  • 8.1 Veterinary Clinics
  • 8.2 Specialty Wellness Providers
  • 8.3 Online and Direct-to-Consumer
  • 8.4 Diagnostic Laboratories

9 Global Pet Longevity and Healthspan Market, By Assessment and Diagnostics

  • 9.1 Preventive Blood and Biomarker Panels
  • 9.2 Genetic and Risk Profiling
  • 9.3 Wearable and Activity Monitoring
  • 9.4 Functional and Mobility Assessment

10 Global Pet Longevity and Healthspan Market, By Intervention Setting

  • 10.1 Primary Veterinary Care
  • 10.2 Specialty Longevity Clinics
  • 10.3 Home-Based Preventive Programs
  • 10.4 Research and Clinical Trial Programs

11 Global Pet Longevity and Healthspan Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Loyal
  • 14.2 Rejuvenate Bio
  • 14.3 Animal Bioscience
  • 14.4 Gallant
  • 14.5 VetStem, Inc.
  • 14.6 Embark Veterinary, Inc.
  • 14.7 Mars Petcare
  • 14.8 Nestle Purina PetCare
  • 14.9 Zoetis Inc.
  • 14.10 Hill's Pet Nutrition
  • 14.11 PetDx
  • 14.12 FidoCure
  • 14.13 Basepaws
  • 14.14 Wisdom Panel
  • 14.15 Bioiberica
Product Code: SMRC41187

List of Tables

  • Table 1 Global Pet Longevity and Healthspan Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pet Longevity and Healthspan Market Outlook, By Intervention Type (2023-2034) ($MN)
  • Table 3 Global Pet Longevity and Healthspan Market Outlook, By Preventive Nutrition and Supplements (2023-2034) ($MN)
  • Table 4 Global Pet Longevity and Healthspan Market Outlook, By Advanced Diagnostics and Biomarkers (2023-2034) ($MN)
  • Table 5 Global Pet Longevity and Healthspan Market Outlook, By Regenerative and Cellular Therapies (2023-2034) ($MN)
  • Table 6 Global Pet Longevity and Healthspan Market Outlook, By Personalized Veterinary Monitoring (2023-2034) ($MN)
  • Table 7 Global Pet Longevity and Healthspan Market Outlook, By Exercise and Mobility Programs (2023-2034) ($MN)
  • Table 8 Global Pet Longevity and Healthspan Market Outlook, By Pet Type (2023-2034) ($MN)
  • Table 9 Global Pet Longevity and Healthspan Market Outlook, By Dogs (2023-2034) ($MN)
  • Table 10 Global Pet Longevity and Healthspan Market Outlook, By Cats (2023-2034) ($MN)
  • Table 11 Global Pet Longevity and Healthspan Market Outlook, By Other Companion Animals (2023-2034) ($MN)
  • Table 12 Global Pet Longevity and Healthspan Market Outlook, By Life Stage (2023-2034) ($MN)
  • Table 13 Global Pet Longevity and Healthspan Market Outlook, By Adult Preventive Care (2023-2034) ($MN)
  • Table 14 Global Pet Longevity and Healthspan Market Outlook, By Mature-Age Healthspan (2023-2034) ($MN)
  • Table 15 Global Pet Longevity and Healthspan Market Outlook, By Senior Longevity Support (2023-2034) ($MN)
  • Table 16 Global Pet Longevity and Healthspan Market Outlook, By Delivery Channel (2023-2034) ($MN)
  • Table 17 Global Pet Longevity and Healthspan Market Outlook, By Veterinary Clinics (2023-2034) ($MN)
  • Table 18 Global Pet Longevity and Healthspan Market Outlook, By Specialty Wellness Providers (2023-2034) ($MN)
  • Table 19 Global Pet Longevity and Healthspan Market Outlook, By Online and Direct-to-Consumer (2023-2034) ($MN)
  • Table 20 Global Pet Longevity and Healthspan Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 21 Global Pet Longevity and Healthspan Market Outlook, By Assessment and Diagnostics (2023-2034) ($MN)
  • Table 22 Global Pet Longevity and Healthspan Market Outlook, By Preventive Blood and Biomarker Panels (2023-2034) ($MN)
  • Table 23 Global Pet Longevity and Healthspan Market Outlook, By Genetic and Risk Profiling (2023-2034) ($MN)
  • Table 24 Global Pet Longevity and Healthspan Market Outlook, By Wearable and Activity Monitoring (2023-2034) ($MN)
  • Table 25 Global Pet Longevity and Healthspan Market Outlook, By Functional and Mobility Assessment (2023-2034) ($MN)
  • Table 26 Global Pet Longevity and Healthspan Market Outlook, By Intervention Setting (2023-2034) ($MN)
  • Table 27 Global Pet Longevity and Healthspan Market Outlook, By Primary Veterinary Care (2023-2034) ($MN)
  • Table 28 Global Pet Longevity and Healthspan Market Outlook, By Specialty Longevity Clinics (2023-2034) ($MN)
  • Table 29 Global Pet Longevity and Healthspan Market Outlook, By Home-Based Preventive Programs (2023-2034) ($MN)
  • Table 30 Global Pet Longevity and Healthspan Market Outlook, By Research and Clinical Trial Programs (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!